|1.||Alitalo, Kari: 10 articles (07/2014 - 02/2005)|
|2.||Carmeliet, Peter: 8 articles (05/2013 - 09/2003)|
|3.||Eriksson, Ulf: 8 articles (10/2012 - 09/2003)|
|4.||Shibuya, Masabumi: 7 articles (06/2015 - 09/2008)|
|5.||Kivelä, Riikka: 6 articles (07/2014 - 07/2006)|
|6.||Ylä-Herttuala, Seppo: 6 articles (12/2012 - 08/2005)|
|7.||Bry, Maija: 5 articles (07/2014 - 10/2008)|
|8.||Li, Xuri: 5 articles (02/2012 - 03/2008)|
|9.||Giacca, Mauro: 4 articles (07/2015 - 05/2010)|
|10.||Zentilin, Lorena: 4 articles (07/2015 - 05/2010)|
10/18/2012 - "Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes."
04/01/2014 - "Recent animal studies indicated that VEGF-B signaling had determinant roles in insulin resistance, lipid distribution and metabolism in type 2 diabetes. "
01/01/2014 - "Additionally, recent studies have shown that Vegf-b deficiency protects from high-fat diet (HFD)-induced diabetes and insulin resistance. "
04/01/2014 - "T-test analysis showed that the associations of serum VEGF-B levels with insulin resistance, pancreatic reserve, HDL and LDL were not significant. "
01/01/2014 - "We found no differences in HFD-induced weight gain, glucose tolerance or insulin resistance between the Vegf-b(-/-) strains and their littermate control mice. "
03/15/1996 - "The VEGF-B gene was found on chromosome 11q13, proximal to the cyclin D1 gene, which is amplified in a number of human carcinomas. "
03/01/2007 - "These findings suggest that, while VEGF-B seems to be useful as a prognostic indicator only in node-positive patients, VEGFR-1 may be an independent poor prognosticator in patients with invasive breast carcinoma."
03/01/2007 - "However, the clinicopathologic and clinical value of VEGF-B and VEGFR-1 in invasive breast carcinoma remains unclear. "
09/01/2005 - "Real-time quantitative RT-PCR analysis was conducted on selected 11 genes (total VEGF-A, VEGF(121), VEGF(165), VEGF(189), VEGF-B, C and D, bFGF, dThdPase, MMP-2 and uPA) using 11 cervical carcinoma cell lines and 14 normal cervical tissues. "
12/01/1997 - "These results imply that a second member of the VEGF family, VEGF-B, may play a significant role in the angiogenesis, progression, and maintenance of ovarian carcinomas."
04/14/2009 - "In vivo, VEGF-B targeting inhibited both choroidal and retinal neovascularization. "
03/01/2008 - "Interestingly, VEGF-B treatment at the dose effective for neuronal survival did not cause retinal neovascularization, suggesting that VEGF-B is the first member of the VEGF family that has a potent antiapoptotic effect while lacking a general angiogenic activity. "
01/01/2011 - "Retinal neovascularization (NV) was assessed at postnatal day 17 in oxygen-induced ischemic retinopathy after intravitreal injection of AAV-VEGF-B in left eyes and AAV-GFP in right eyes at postnatal day 7. Two weeks after injection of AAV vectors, choroidal NV was generated by laser photocoagulation and assessed 2 weeks later. "
06/01/2003 - "These results suggest that VEGF-A and VEGF-B play a role early in tumour development at the stage of adenoma formation and that VEGF-C plays a role in advanced disease when there is more likelihood of metastatic spread. "
06/01/2003 - "A significantly greater amount of VEGF-C mRNA was present in carcinomas compared with adenomas (p = 0.03), whereas there was a significant reduction of VEGF-B in carcinomas compared with adenomas (p = 0.0002). "
06/01/2003 - "VEGF-A and VEGF-B mRNAs were significantly more abundant in adenomas (p = 0.0003 and p = 0.04 respectively) compared with normal tissues, while VEGF-A and VEGF-C were significantly increased in carcinomas compared with normal tissues (p = 0.0006 and p = 0.0009 respectively). "
06/01/2003 - "The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression."
06/01/2003 - "We measured the gene expression of VEGF ligands (VEGF-A, VEGF-B, VEGF-C, and VEGF-D) and their receptors (VEGFR-1, VEGFR-2, and VEGFR-3), in normal colorectal tissues (n = 20), adenomas (n = 10), and in CRC (n = 71) representing different Duke's stages using ribonuclease protection assay, semi-quantitative relative reverse transcriptase polymerase chain reaction, together with the pattern of their expression by immunohistochemistry. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Vascular Endothelial Growth Factor C
|3.||Messenger RNA (mRNA)
|4.||Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)
|6.||Vascular Endothelial Growth Factor D
|7.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|8.||Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
|9.||Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
|10.||Vascular Endothelial Growth Factors
|1.||Heterologous Transplantation (Xenotransplantation)